About This Webinar
Until now osteoporosis management has focused on making a diagnosis and commencing oral antiresorptive treatment early. Secondary care referral for parenteral antiresorptive or anabolic treatment is considered for those who fail or are intolerant to first line treatment. However, despite treatment a significant proportion of patients continue to fracture.

Recent studies have shown better fracture prevention by using anabolic drugs, such as romosozumab, early when compared to alendronate. Therefore we may be able to narrow the treatment gap by re-designing osteoporosis pathways to use anabolic drugs earlier for those patients with the highest imminent fracture risk.
Presenter
  • 1601626945-874c8fa307145204
    Dr Katie Moss
    Consultant Rheumatologist, St George’s University Hospitals NHS Foundation Trust

    Dr Katie Moss qualified from Bristol University in 1992 and achieved MRCP in 1997. She completed specialist training in 2003 and attained FRCP in 2008.

    In 2004 she was appointed Rheumatology Consultant at St George’s Hospital, London where she leads the Osteoporosis and Metabolic Bone Disease service.

    She has a special interest in hypophosphatasia. Her specialist roles include treating adults with asfotase alfa and contributing to NIHR research.

    Katie is on the board for numerous national committees, including: NOGG; and NICE Asfotase Alfa for treatment of hypophosphatasia MAA Oversight committee.

    She contributes to medical education at St George’s, University of London where she is an honorary senior lecturer.
Powered by BigMarker